---
title: "Inhibrx Biosciences Inc. Metrics Guide"
description: "Inhibrx Biosciences Inc. revenue, margins, cash flow and balance sheet figures by fiscal year, taken from its SEC filings, with the ratios explained."
canonical: https://www.getswoopr.com/stocks/companies/inhibrx-biosciences-inc/financial-metrics/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Inhibrx Biosciences Inc. Financial Metrics Guide

## Direct Answer

> Inhibrx Biosciences Inc. reported revenue of $1 million for the fiscal year ended December 31, 2025, with an operating margin of -10386.5% and net income of -$140 million, according to its SEC filings. Revenue grew 550.0% from the prior year.

## What Are Inhibrx Biosciences Inc.'s Key Financial Figures?

| Fiscal year | FY2025ended December 31, 2025 | FY2024ended December 31, 2024 | FY2023ended December 31, 2023 |
| --- | --- | --- | --- |
| Revenue | $1 million | $200,000 | $2 million |
| Operating income | -$135 million | -$331 million | -$219 million |
| Operating margin | -10386.5% | -165724.0% | -12178.9% |
| Net income | -$140 million | $1.7 billion | -$241 million |
| Net margin | -10773.5% | 843786.0% | -13408.9% |
| Operating cash flow | -$130 million | -$194 million | -$193 million |
| Capital expenditures | $31,000 | $3 million | $5 million |
| Free cash flow | -$130 million | -$197 million | -$198 million |

Operating margin widened by 155337.5 percentage points between fiscal 2024 and 2025, which separates pricing and cost discipline from revenue growth alone. Free cash flow (operating cash flow minus capital expenditures) was -$130 million against net income of -$140 million; cash generation covered reported earnings.

![Bar chart of Inhibrx Biosciences Inc. revenue, operating income, net income for fiscal 2023 to 2025. In fiscal 2025, revenue was $1 million, operating income negative $135 million and net income negative $140 million.](https://www.getswoopr.com/images/charts/inhibrx-biosciences-inc-metrics-revenue-profit.webp)
*Inhibrx Biosciences Inc. revenue, operating income and net income by fiscal year, from the figures in the table above. Select the chart to open it full size.*

![Line chart of Inhibrx Biosciences Inc. operating margin and net margin for fiscal 2023 to 2025. In fiscal 2025, operating margin was -10386.5% and net margin was -10773.5%.](https://www.getswoopr.com/images/charts/inhibrx-biosciences-inc-metrics-margins.webp)
*Inhibrx Biosciences Inc. operating margin and net margin by fiscal year: operating income and net income as a share of revenue. Select the chart to open it full size.*

![Bar chart of Inhibrx Biosciences Inc. operating cash flow, capital expenditures, free cash flow for fiscal 2023 to 2025. In fiscal 2025, operating cash flow was negative $130 million, capital expenditures was $31,000, free cash flow was negative $130 million.](https://www.getswoopr.com/images/charts/inhibrx-biosciences-inc-metrics-cash-flow.webp)
*Inhibrx Biosciences Inc. operating cash flow, capital expenditures and free cash flow by fiscal year. Select the chart to open it full size.*

## What Does Inhibrx Biosciences Inc.'s Balance Sheet Show?

| Cash and cash equivalents | $124 million |
| --- | --- |
| Long-term debt | $101 million |
| Total assets | $146 million |
| Total liabilities | $138 million |
| Shareholders' equity | $8 million |
| Current ratio | 3.9x |

Balance sheet values are as of the end of fiscal 2025. Income statement figures describe a whole year; balance sheet figures describe a single day, so the two answer different questions.

## Where These Numbers Come From

Every figure on this page is a value Inhibrx Biosciences Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0002007919-26-000006 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 7, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.

Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.

## Frequently Asked Questions

### What was Inhibrx Biosciences Inc.'s revenue in fiscal 2025?

Inhibrx Biosciences Inc. reported revenue of $1 million for the fiscal year ended December 31, 2025, according to its SEC filings.

### What is Inhibrx Biosciences Inc.'s operating margin?

Inhibrx Biosciences Inc.'s operating margin was -10386.5% in fiscal 2025: operating income of -$135 million on revenue of $1 million.

### How much free cash flow did Inhibrx Biosciences Inc. generate?

Operating cash flow of -$130 million less capital expenditures of $31,000 gives free cash flow of -$130 million for fiscal 2025.

## References

- [SEC EDGAR: Inhibrx Biosciences, Inc. Form 10-K filed March 19, 2026](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000006/inbx-20251231.htm)
- [SEC EDGAR: Inhibrx Biosciences, Inc. annual and quarterly filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=2007919&type=10-K)
- [SEC: EDGAR application programming interfaces (XBRL frames and submissions data)](https://www.sec.gov/search-filings/edgar-application-programming-interfaces)

## Related Pages

- [Inhibrx Biosciences Inc. company dossier](https://www.getswoopr.com/stocks/companies/inhibrx-biosciences-inc/)
- [Inhibrx Biosciences Inc. financial metrics](https://www.getswoopr.com/stocks/companies/inhibrx-biosciences-inc/financial-metrics/)
- [Inhibrx Biosciences Inc. financial risk indicators](https://www.getswoopr.com/stocks/companies/inhibrx-biosciences-inc/risks-monitoring/)
- [Inhibrx Biosciences Inc. business model and revenue mix](https://www.getswoopr.com/stocks/companies/inhibrx-biosciences-inc/business-model/)
- [Fundamental analysis guides](https://www.getswoopr.com/learn/fundamental-analysis/)

[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)

Swoopr's editorial team produces independent investment education content. Content is for educational purposes only and does not constitute personalized investment advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).